SETBP1 and acute myeloid leukemia: Furthermore, MECOM, a SETBP1 direct target whose upregulation has been previously associated with SETBP1 GoF mutation41 and BMF42; CDK6, that acts as a transcriptional regulator to suppress EGR143 and it is usually overexpressed in AML cells; ETS1, involved in granulocyte differentiation and found overexpressed in patients with chronic myeloid leukemia44, were found open in all conditions (Figs. 2E, 3A; Supplementary Figs. 3B and 4A).